-- Improved sample quality, workflow efficiencies and flexibility drive transition to Hologic platform
MANCHESTER, England, April 8, 2015 /PRNewswire/ -- Hologic, Inc. (NASDAQ: HOLX) today announced that Luxembourg's National Health Laboratory, which operates under the Ministry of Health, has successfully implemented the Company's comprehensive product platform for its cervical cancer screening programme. The conversion to Hologic's cervical screening technologies includes the ThinPrep Pap test and imaging system, Aptima HPV assays, the Tomcat pre-analytical processing instrument, and the fully automated, sample-to-answer Panther system.
"We are very pleased to partner with the National Health Laboratory and support their cervical cancer screening programme," said Claus Egstrand, Hologic Group President, International. "Our innovative assays and advanced automation platforms work together seamlessly to accurately and efficiently detect cervical disease at its earliest stage, when the likelihood of an improved patient outcome is at its greatest. This partnership provides us with the opportunity to make our world class portfolio of cervical screening technologies more accessible to physicians and patients in Luxembourg."
"Hologic has been a very responsive partner over the last year as we transitioned to their cervical screening platform," said Dr. Marc Fischer, Cytology Laboratory Manager at the National Health Laboratory. "Our decision to convert to Hologic's cervical health solutions was based on improved sample quality with ThinPrep, greater workflow efficiencies and scalability with the Panther system, and the flexibility to expand our cytology capabilities to include HPV screening in the future."
Luxembourg has an estimated population of over 200,000 women ages 15 and older who are at risk of developing cervical cancer. Under current Luxembourg guidelines, initial cervical screening should take place at age 20 with follow-up screening intervals of one to three years.
About Hologic Advanced Cervical Screening Solutions
Cervical cancer is one of the most common cancers among women in the world, and HPV is responsible for more than 99% of all cervical cancers. Hologic's ThinPrep Pap test is one of the most widely used methods for cervical screening.
The Aptima HPV assay is a nucleic acid amplification test that detects 14 high-risk strains of human papillomavirus (HPV) mRNA associated with cervical cancer and precancerous lesions from the E6/E7 oncogenes. The Aptima HPV assay can be used with ThinPrep liquid cytology specimens, either before or after the sample has been processed for cytology testing on a ThinPrep slide processor. With this solution, Hologic enables co-testing and triage testing with cytology and HPV from one sample to be executed efficiently and in a high quality.
Hologic's automation platforms are designed to improve productivity, enhance chain-of-custody procedures and deliver reliable, reproducible results. Tomcat is a fully automated general purpose instrument designed to ease the strain of pre-analytical sample processing by eliminating the inefficient and error-prone activities required to manually aliquot samples. The Panther system is a scalable testing platform for virtually any size lab environment. A fully automated, sample-to-answer instrument, the Panther system eliminates the need for batch processing and automates all aspects of nucleic acid amplification testing on a single, integrated platform.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company's core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure. For more information on Hologic, visit www.hologic.com.
Hologic, Aptima, Panther, ThinPrep, The Science of Sure, Tomcat and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Forward-looking Statement Disclaimer
This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic's ThinPrep Pap test platform, Aptima HPV assays and the Tomcat instrument and Panther system. There can be no assurance the assays and systems will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the assays and systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statements are based.
SOURCE Hologic, Inc.